New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
08:35 EDTBMRNBioMarin should be bought on any weakness, says RW Baird
Baird recommends taking advantage of any weakness in BioMarin following its positive announcement the BMN-701 met the criteria to advance to Phase ll/lll. The firm believes the announcement was tempered by the proposed path to registration and clinical endpoints but could still be meaningfully differentiated from its existing competitor. Shares are Outperform rated with a $63 price target.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
08:22 EDTBMRNBioMarin says FDA extends Kuvan market exclusivity by six months
Subscribe for More Information
April 7, 2014
10:04 EDTBMRNBioMarin well positioned for revenue growth, says Summer Street
Subscribe for More Information
April 2, 2014
11:55 EDTBMRNUniqure rises after Baxter acquires Chatham Therapeutics
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use